Diagnostic Values of Free Triiodothyronine and Free Thyroxine and the Ratio of Free Triiodothyronine to Free Thyroxine in Thyrotoxicosis

被引:25
作者
Chen, Xinxin [1 ]
Zhou, Yulin [1 ]
Zhou, Mengxi [1 ]
Yin, Qinglei [1 ]
Wang, Shu [1 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Med, Shanghai Clin Ctr Endocrine & Metab Dis, Dept Endocrinol,Ruijin Hosp, 197 Ruijin 2nd Rd, Shanghai 200025, Peoples R China
基金
中国国家自然科学基金;
关键词
SERUM-FREE TRIIODOTHYRONINE; GRAVES-DISEASE; HYPERTHYROIDISM; DEIODINASE; TYPE-1;
D O I
10.1155/2018/4836736
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. The results of previous studies on the usefulness of free triiodothyronine (FT3) to free thyroxine (FT4) are controversial. We investigated the usefulness of FT3, FT4, and FT3/FT4 ratio in differentiating Graves' disease (GD) from destructive thyroiditis. Methods. A total of 126 patients with untreated GD, 36 with painless thyroiditis, 18 with painful subacute thyroiditis, and 63 healthy controls, were recruited. The levels of FT3 and FT4 and the FT3/FT4 ratios for the different etiologies of thyrotoxicosis were evaluated separately by receiver operating characteristic (ROC) curve analysis. The expression levels of type 1 and type 2 deiodinase (DIO1 and DIO2) in thyroid tissues were also investigated. Results. The optimal cut-off values were 7.215 pmol/L for FT3, 21.71 pmol/L for FT4, and 0.4056 for the FT3/FT4 ratio. The specificity and positive predictive value of the FT3/FT4 ratio were highest for values > 0.4056. DIO1 mRNA expression was significantly higher in the thyroid tissue of patients with GD (P = 0 013). Conclusions. We demonstrated that the FT3/FT4 ratio was useful in differentiating GD from destructive thyroiditis. In addition, a relatively high expression of type 1 deiodinase in the thyroid might be responsible for the high FT3/FT4 ratio in patients with GD.
引用
收藏
页数:8
相关论文
共 18 条
[1]   Techniques to quantify TSH receptor antibodies [J].
Ajjan, R. A. ;
Weetman, A. P. .
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2008, 4 (08) :461-468
[2]   Thyrotropin receptor antibodies: new insights into their actions and clinical relevance [J].
Ando, T ;
Latif, R ;
Davies, TF .
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 19 (01) :33-52
[3]  
Bartha T., 2003, ENDOCRINOLOGY, V141, P229
[4]   Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases [J].
Bianco, AC ;
Salvatore, D ;
Gereben, B ;
Berry, MJ ;
Larsen, PR .
ENDOCRINE REVIEWS, 2002, 23 (01) :38-89
[5]   Isolation of human type 2 deiodinase gene promoter and characterization of a functional cyclic adenosine monophosphate response element [J].
Canettieri, G ;
Celi, FS ;
Baccheschi, G ;
Salvatori, L ;
Andreoli, M ;
Centanni, M .
ENDOCRINOLOGY, 2000, 141 (05) :1804-1813
[6]   Determinants of serum T4 and T3 at the time of diagnosis in nosological types of thyrotoxicosis: a population-based study [J].
Carle, Allan ;
Knudsen, Nils ;
Pedersen, Inge Bulow ;
Perrild, Hans ;
Ovesen, Lars ;
Rasmussen, Lone Banke ;
Laurberg, Peter .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2013, 169 (05) :537-545
[7]   Type 1 and type 2 iodothyronine deiodinases in the thyroid gland of patients with 3,5,3′-triiodothyronine-predominant Graves' disease [J].
Ito, Mitsuru ;
Toyoda, Nagaoki ;
Nomura, Emiko ;
Takamura, Yuuki ;
Amino, Nobuyuki ;
Iwasaka, Toshiji ;
Takamatsu, Junta ;
Miyauchi, Akira ;
Nishikawa, Mitsushige .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2011, 164 (01) :95-100
[8]   Simple and practical parameters for differentiation between destruction-induced thyrotoxicosis and Graves' thyrotoxicosis [J].
Izumi, Y ;
Hidaka, Y ;
Tada, H ;
Takano, T ;
Kashiwai, T ;
Tatsumi, K ;
Ichihara, K ;
Amino, N .
CLINICAL ENDOCRINOLOGY, 2002, 57 (01) :51-58
[9]   Biochemical mechanisms of thyroid hormone deiodination [J].
Kuiper, GGJM ;
Kester, MHA ;
Peeters, RP ;
Visser, TJ .
THYROID, 2005, 15 (08) :787-798
[10]  
LARSEN PR, 1981, ENDOCR REV, V2, P87, DOI 10.1210/edrv-2-1-87